Skip to main content
Michael Grever, MD, Oncology, Columbus, OH, Ohio State University Wexner Medical Center

MichaelR.GreverMD

Oncology Columbus, OH

Professor of Medicine, Ohio State University

Dr. Grever is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Grever's full profile

Already have an account?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1976 - 1978
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 1971 - 1974
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1971

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1978 - 2025
  • MD State Medical License
    MD State Medical License 1991 - 2008
  • PA State Medical License
    PA State Medical License 1972 - 1976
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2008-2014
  • America's Top Doctors for Cancer Castle Connolly, 2007-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
    Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
    Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
    Michael R. Grever, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Challenges In Management Of Hairy Cell Leukemia In 2019 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

  • Phase I Trials Of Anti-Cancer AgentsNational Cancer Institute2003–2012
  • Pre-Clinical And Clinical Development Of Silvestrol In Chronic LymphocyticNational Cancer Institute2009–2011
  • Par04-122, Extramural Research Facilities Improvement P*National Center For Research Resources2010
  • Signal Transduction And Kinase Inhibition In CLLNational Cancer Institute2006–2010
  • Molecular Studies Of Drug Resistance In Chronic LymphocyNational Cancer Institute2000–2003
  • Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2002
  • Phase II Clinical Trials ConsortiumNational Cancer Institute1994–2000
  • Phase II Study Of 9-Aminocamptothecin In Chronic Lymphocytic LeukemiaNational Center For Research Resources1997–1999
  • CalgbNational Cancer Institute1998
  • Southwest Oncology GroupNational Cancer Institute1985–1997
  • Oncology Training GrantNational Cancer Institute1985–1997
  • Core--Interdisciplinary Oncology UnitNational Cancer Institute1985–1994
  • OncologyNational Cancer Institute1988–1992
  • Deoxycoformycin In Lymphoid MalignanciesNational Cancer Institute1985–1986

Professional Memberships

Hospital Affiliations